Skip to main contentAI and Advanced
/
ONESOURCE · NSEMarket ticker unavailable · configure an authorised index feed
ON
NSE · Equity shares · Biotechnology & Drugs-21.80 · -1.35%
Onesource Specialty Pharma ONESOURCE
NSE:INR 1,592.2
BSE:INR 1,545.55
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for ONESOURCE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,614
Day rangeINR 1,563.2 — INR 1,613.6
52-week rangeINR 1,057 — INR 1,925
Volume1.43 L
Market cap17,722.82
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,421.59
Net Income (INR Cr)-73.8
EPS-5.88
Research path: Interpret Onesource Specialty Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ONESOURCEOnesource Specialty Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 8,210.01 | 7,550.24 | 1,308.61 |
| Cash Equivalents | 61.89 | 45.17 | 53.86 |
| Other Liabilities Total | 19.41 | 18.35 | 2.4 |
| Accrued Expenses | 12.87 | 32.13 | 24.3 |
| Long Term Debt | 563.7 | 219.33 | 271.59 |
| Common Stock Total | 11.46 | 11.44 | 4.01 |
| Other Current Assets Total | 177.27 | 99.37 | Not available |
| Total Assets | 8,210.01 | 7,550.24 | 1,308.61 |
| Current Portof LT Debt/Capital Leases | 721.44 | 123.9 | 156.73 |
| Cash | 35.68 | 156.48 | 6.47 |
| Total Equity | 5,831.29 | 5,880.58 | 395.71 |
| Long Term Investments | 10.22 | 6.91 | 3.79 |
| Retained Earnings(Accumulated Deficit) | 5,819.83 | -1,831.15 | -1,812.26 |
| Total Common Shares Outstanding | 11.46 | 11.44 | 11.44 |
| Tangible Book Valueper Share Common Eq | 45.75 | 43.9 | 6.14 |
| Goodwill Net | 3,827.53 | 3,827.53 | Not available |
| Total Liabilities | 2,378.73 | 1,669.66 | 912.9 |
| Total Debt | 1,503.94 | 942.44 | 571.17 |
| Short Term Investments | 21.92 | 8.88 | 15.79 |
| Cashand Short Term Investments | 119.49 | 210.53 | 76.12 |
| Total Receivables Net | 690.22 | 556.35 | 74.41 |
| Deferred Income Tax | 134.85 | 155.22 | Not available |
| Accounts Receivable-Trade Net | 690.22 | 422.78 | 55.24 |
| Property/Plant/Equipment Total-Net | 1,239.75 | 957.73 | 725.17 |
| Total Current Liabilities | 1,441.97 | 1,113.56 | 630.59 |
| Total Inventory | 438.96 | 207.18 | 22.74 |
| Accounts Payable | 374.55 | 175.51 | 81.02 |
| Other Currentliabilities Total | 333.1 | 346.01 | 234.01 |
| Total Long Term Debt | 782.5 | 382.53 | 279.91 |
| Intangibles Net | 1,479.42 | 1,550.67 | 325.45 |
| Other Long Term Assets Total | 227.16 | 18.31 | 4.91 |
| Note Receivable-Long Term | 0 | 102.92 | 72.92 |
| Total Current Assets | 1,425.94 | 1,086.18 | 176.38 |
| Capital Lease Obligations | 218.79 | 163.19 | 8.32 |
| Accumulated Depreciation Total | Not available | -356.29 | -423.73 |
| Other Equity Total | Not available | 2.06 | Not available |
| Prepaid Expenses | Not available | 12.76 | 3.11 |
| Additional Paid-In Capital | Not available | 7,698.23 | 2,203.96 |
| Property/Plant/Equipment Total-Gross | Not available | 1,253.64 | 1,148.89 |
| Notes Payable/Short Term Debt | Not available | 436.01 | 134.53 |
Fundamentals
Valuation and ratios
Margins
Operating Margin 12m2.9
Net Profit Margin 12m-3.15
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio12.47
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk42.84
Analyst consensus
ConsensusStrong Buy
Consensus score1.25
Analyst opinions4
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count3
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 30.48%
- FII
- 19.19%
- MF
- 12.98%
- Other
- 37.35%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
OneSource Specialty Pharma to discuss Q1FY27 results on Jul 25 - scanx.tradeMarket news · 21 Jul 2026, 12:34 pm
OneSource Specialty Pharma to discuss Q1FY27 results on Jul 25 scanx.trade
OneSource partners Formycon for biosimilars manufacturing - scanx.tradeMarket news · 15 Jul 2026, 12:30 pm
OneSource partners Formycon for biosimilars manufacturing scanx.trade
Formycon AG and OneSource Specialty Pharma Announce Strategic Manufacturing Partnership for Biosimilars - Yahoo FinanceMarket news · 15 Jul 2026, 2:08 am
Formycon AG and OneSource Specialty Pharma Announce Strategic Manufacturing Partnership for Biosimilars Yahoo Finance
OneSource, Formycon Partner on Biosimilar Manufacturing - Contract PharmaMarket news · 14 Jul 2026, 6:19 pm
OneSource, Formycon Partner on Biosimilar Manufacturing Contract Pharma
OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars - The Economic TimesMarket news · 14 Jul 2026, 2:03 pm
OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars The Economic Times
OneSource Pharma, Formycon AG Partner for Biosimilars - Rediff MoneyWizMarket news · 14 Jul 2026, 1:51 pm
OneSource Pharma, Formycon AG Partner for Biosimilars Rediff MoneyWiz
Corporate actions
Events
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- annual General MeetingPOM
- annual General MeetingPOM
Rusaka Markets Community
Discussion and sentiment for Onesource Specialty Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. It operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The Company specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The Company caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ONESOURCE
- BSE Code
- 544292
Questions
Stock FAQ
What is the symbol and ISIN of Onesource Specialty Pharma?
Onesource Specialty Pharma has the symbol ONESOURCE and ISIN - INE013P01021.
What is the current price of Onesource Specialty Pharma?
Onesource Specialty Pharma is currently trading at INR 1,592.20.
What are the year high and year low of Onesource Specialty Pharma?
Onesource Specialty Pharma has a year high of INR 1,925.00 and a year low of INR 1,057.00.
What is the market capitalization of Onesource Specialty Pharma?
Onesource Specialty Pharma has a market capitalization of INR 17,722.82 crore.
What is the P/E ratio of Onesource Specialty Pharma?
Onesource Specialty Pharma has a P/E ratio of NA.
What is the dividend yield of Onesource Specialty Pharma?
Onesource Specialty Pharma has a dividend yield of 0.00%.
How is the financial performance of Onesource Specialty Pharma based on revenue, net income, and EPS?
Onesource Specialty Pharma has revenue of INR 1,421.59 crore, net income of INR -73.80 crore, and EPS of INR -3.61.
What is the book value of Onesource Specialty Pharma?
Onesource Specialty Pharma has a book value of NA.
What is the debt-to-equity ratio of Onesource Specialty Pharma?
Onesource Specialty Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Onesource Specialty Pharma?
Onesource Specialty Pharma has a price-to-book ratio of NA and a price-to-sales ratio of 12.47.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.